Starting with transplants of human oligodendrocytes in the late 1980s [40], and more recently with populations of
human oligodendrocyte progenitor cells isolated from the developing or adult CNS, or from human embryonic stem cells, it has been possible to generate extensive myelination upon transplantation into spinal cord injury or into congenital mouse models of hypomyelination [41]--[48].
Not exact matches
At the International Society for Stem
Cell Research 2017 Annual Meeting (June 14 - 17, 2017; Boston, USA), Asterias Biotherapeutics, Inc (CA, USA) will present new 9 - month efficacy and safety data from their ongoing SCiStar Phase I / IIa trial of human embryonic stem cell - derived oligodendrocyte progenitor ce
Cell Research 2017 Annual Meeting (June 14 - 17, 2017; Boston, USA), Asterias Biotherapeutics, Inc (CA, USA) will present new 9 - month efficacy and safety data from their ongoing SCiStar Phase I / IIa trial of
human embryonic stem
cell - derived oligodendrocyte progenitor ce
cell - derived
oligodendrocyte progenitor cells.
Preclinical Safety of
Human Embryonic Stem
Cell - Derived
Oligodendrocyte Progenitors Supporting Clinical Trials In Spinal Cord Injury.
Immunological properties of
human embryonic stem
cell - derived
oligodendrocyte progenitor cells.
Human Embryonic Stem
Cell - Derived
Oligodendrocyte Progenitor Cell Transplants Improve Recovery After Cervical Spinal Cord Injury.
AST - OPC1, an
oligodendrocyte progenitor cell population derived from
human embryonic stem
cells, has been shown in preclinical testing in animals and in vitro to have three potentially reparative functions that address the complex pathologies observed in demyelination disorders, such as spinal cord injuries, and multiple neurodegenerative diseases, including multiple sclerosis and white matter stroke.